From: Auricular neural stimulation as a new non-invasive treatment for opioid detoxification
Treatment | Primary Mechanism of Action | FDA Approval Status | Pros | Cons | References |
---|---|---|---|---|---|
Buprenorphine | Mu receptor partial agonist | Approved | 1. Ceiling effect to prevent overdose. 2. Prevents euphoria due to partial agonism therapy. 3. Long-term injection formulation is available. 4. Naloxone conjunction prevents misuse. | 1. Long term may lead to reduced libido. 2. May cause nausea and constipation. 3. Potential dependence on higher dosage. | |
Methadone | Mu receptor full agonist | Approved | 1. Effective in resistant cases of opioid dependence. 2. Effective in HIV and HCV infectious states 3. Favorable prognostic outcome with history of non- compliance. | 1. Close supervision for its administration is required. 2. More risk of sustaining dependence and GI related side effects. 3. Increased risk of overdose if taken in conjunction with other controlled sedatives. | (Mattick et al. 2008; Eap et al. 2002; Bell and Strang 2020) |
Naltrexone | Mu receptor antagonist | Approved | 1. Effective in co-existing alcohol and opioid dependence. 2. Prevents reinforcing effects of opioid use. 3. Long-term injection formulation is available. | 1. Avoid in advanced liver diseases. 2. Caution in those who have underlying severe depressive illness. | |
Lofexidine | Alpha 2 receptor agonist | Approved | 1. Effective in withdrawal state driven by high sympathetic flow. 2. Facilitates detoxification from opioids. 3. First FDA approved non-opioid medication. | 1. May precipitate sedation, drowsiness. 2. Blood pressure monitoring required - Risk of inducing hypotension. | (McCambridge et al. 2007; Pergolizzi Jr. et al. 2019; Gerra et al. 2001; Kuszmaul et al. 2019) |
Clonidine | Alpha 2 receptor agonist | Off label | 1. Ameliorates withdrawal symptoms. 2. Helps in alleviating anxiety and restlessness associated with withdrawal. | 1. Caution for sudden hypotension. 2. Precipitates sedation and dizziness | |
Baclofen | GABA-B receptor agonist | Off label | 1. Alleviates muscle spasms. 2. Facilitates detoxification course through muscular symptom neutralization | 1. Abuse potential. 2. Sedations, drowsiness and dizziness as part of side effects | |
Benzodiazepines | Increase effectiveness of GABA-A receptor complex | Off label | 1. Rapid relief of symptoms | 1. Highly addictive. 2. Severe side effects including respiratory depression. | |
Neural Stimulation | Stimulation of V, VII, IX, X cranial nerves | Approved | 1. First FDA approved non systemic based device for alleviation of withdrawal symptoms. 2. Reduces use of medications during acute withdrawal. 3. Non-invasive, well tolerable, with no major side effects. | 1. Cost-effectiveness unknown 2. Studies for long-term use are not available |